https://questpharmatech.com/wp-content/uploads/2020/06/NR04062020.pdf "Quest also announces that Dual held a shareholders' meeting in Korea on May 22, 2020 at which time shareholders approved the change of Dual's name to "OncoQuest Pharmaceuticals Inc.", the election of 8 board members, including the following 4 nominees from OncoQuest, and appointment of Dr. Madi R. Madiyalakan, CEO of Quest and OncoQuest as Chairman of the Board of Dual:
Jonathan S. Berek, MD, MMS, Professor at the Stanford University School of Medicine, Director, Stanford Women's Cancer Center, Senior Advisor, Stanford Cancer Institute.
Michael A. Hollingsworth, Ph.D, Professor at the Cancer Institute at Nebraska University Medical Center (Eppley Institute) and Associate Director, National Cancer Institute (UNMC).
J. Mark Lievonen, MBA, FCPA, FCA, member of the Order of Canada and former President of Sanofi Pasteur Limited.
Madi R. Madiyalakan, Ph.D, CEO of Quest and OncoQuest"
G1945V